A detailed history of Barclays PLC transactions in Kamada LTD stock. As of the latest transaction made, Barclays PLC holds 926 shares of KMDA stock, worth $5,463. This represents 0.0% of its overall portfolio holdings.

Number of Shares
926
Previous 926 -0.0%
Holding current value
$5,463
Previous $5,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 07, 2023

BUY
$4.86 - $5.83 $4,500 - $5,398
926 New
926 $5,000
Q4 2021

Feb 14, 2022

SELL
$5.21 - $6.82 $31 - $40
-6 Closed
0 $0
Q3 2021

Nov 09, 2021

SELL
$5.25 - $5.87 $467 - $522
-89 Reduced 93.68%
6 $0
Q2 2021

Aug 13, 2021

SELL
$5.67 - $6.33 $12,774 - $14,261
-2,253 Reduced 95.95%
95 $1,000
Q1 2021

May 13, 2021

BUY
$6.02 - $8.06 $13,532 - $18,118
2,248 Added 2248.0%
2,348 $14,000
Q4 2020

Feb 11, 2021

BUY
$6.3 - $8.46 $630 - $846
100 New
100 $1,000

Others Institutions Holding KMDA

About KAMADA LTD


  • Ticker KMDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 44,800,500
  • Market Cap $264M
  • Description
  • Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytop...
More about KMDA
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.